WeightWatchers guzzles wonder weight-loss pills
WW, formerly known as WeightWatchers, is using the new diet drugs in its programmes.
Shares in diet group WW (formerly WeightWatchers) climbed by 7% recently after US television personality Oprah Winfrey, a board member and one its largest investors, said she was taking weight-loss medication as a “maintenance tool”, says Erich Schwartzel in The Wall Street Journal.
Her statement introduces “star wattage” to the debate about weight-loss drugs that have “rocked the pharmaceutical, food and diet industries since their widespread adoption”. Her comments come as the company has begun its long-awaited shift to incorporate such prescriptions alongside its... “iconic count-your-points eating plan”, in the hope it will help WeightWatchers stock “reverse a steep, years-long decline”.
WW’s change of plan is a “significant shift” for a company that has long focused on “behaviour-based strategies” such as alterations in diet and exercise, counting calories and “relying on a community of support”, says Alice Park for Time magazine. The shift began in 2018 when it ditched the WeightWatchers name to emphasise “wellness”.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
In 2023 it bought digital health company Sequence, and will now, for an extra $99 a month, offer members digital consultations allowing them to get prescriptions for weight-loss drugs such as semaglutide (Ozempic and Wegovy) and Eli Lilly's tirzepatide (Zepbound). They have proven to be “more effective than any previous weight-loss drugs”. The decision to build a business “around pushing pharmaceuticals” is a clever way to embrace the threat of drugs that might otherwise make WW seem “obsolete”, says Lauren Silva Laughlin on Breakingviews.
Early results seem to suggest it is working, with the number of clinical subscribers at WW jumping far more quickly than expected while latching on to the hype surrounding Wegovy has given the stock a fillip of 60%.
While giving their customers an easier path to a drug in short supply gives WW an “edge”, the key will be “whether WW can break out of the familiar cycle of customers ambitiously signing up for weight-loss programmes, only to fail and drop their subscriptions”. The Wegovy boom has also been good news for its manufacturer Novo Nordisk, say Jonas Ekblom and Lisa Pham on Bloomberg. The stock has risen by 42% this year as investors “latched on to the growth potential of a market that some analysts predict could reach $100bn by 2030”. However, while this surge has “pushed the Danish firm’s value past the size of its domestic economy”, repeating the trick “won’t be so easy” thanks to “rising competition, issues with producing enough of its blockbuster drugs, and a valuation that’s getting stretched”. In addition to Eli Lilly’s Zepbound, cheaper than Wegovy, drugs from Zealand Pharma as well as Amgen are on the horizon.
This article was first published in MoneyWeek's magazine. Enjoy exclusive early access to news, opinion and analysis from our team of financial experts with a MoneyWeek subscription.
Sign up to Money Morning
Our team, led by award winning editors, is dedicated to delivering you the top news, analysis, and guides to help you manage your money, grow your investments and build wealth.
Matthew graduated from the University of Durham in 2004; he then gained an MSc, followed by a PhD at the London School of Economics.
He has previously written for a wide range of publications, including the Guardian and the Economist, and also helped to run a newsletter on terrorism. He has spent time at Lehman Brothers, Citigroup and the consultancy Lombard Street Research.
Matthew is the author of Superinvestors: Lessons from the greatest investors in history, published by Harriman House, which has been translated into several languages. His second book, Investing Explained: The Accessible Guide to Building an Investment Portfolio, is published by Kogan Page.
As senior writer, he writes the shares and politics & economics pages, as well as weekly Blowing It and Great Frauds in History columns He also writes a fortnightly reviews page and trading tips, as well as regular cover stories and multi-page investment focus features.
Follow Matthew on Twitter: @DrMatthewPartri
-
Ofgem proposes new energy tariffs with low or no standing changes
Standing charges have invited public backlash as households battle high energy bills
By Katie Williams Published
-
Google shares bounce on Gemini 2.0 launch
Google has launched the latest version of its Gemini AI platform, and markets have responded positively. Is it time to buy Google shares?
By Dan McEvoy Published
-
Warren Buffet invests in Domino’s – should you buy?
What makes Domino's a compelling investment for Warren Buffet's Berkshire Hathaway, and should you buy the UK-listed takeaway pizza chain?
By Dr Matthew Partridge Published
-
4Imprint makes a strong impression – should you buy?
4Imprint, a specialist in marketing promotional products, is the leader in a fragmented field
By Dr Mike Tubbs Published
-
Invest in Glencore: a cheap play on global growth
Glencore looks historically cheap, yet the group’s prospects remain encouraging
By Rupert Hargreaves Published
-
Should you invest in Trainline?
Ticket seller Trainline offers a useful service – and good prospects for investors
By Dr Matthew Partridge Published
-
Key takeaways from the MoneyWeek Summit 2024: Investing in a dangerous world
If you couldn’t get a ticket to MoneyWeek’s summit, here’s an overview of what you missed
By MoneyWeek Published
-
DCC: a top-notch company going cheap
DCC has a stellar long-term record and promising prospects. It has been unfairly marked down
By Jamie Ward Published
-
How investors can use options to navigate a turbulent world
Explainer Options can be a useful solution for investors to protect and grow their wealth in volatile times.
By James Proudlock Published
-
Invest in Hilton Foods: a tasty UK food supplier
Hilton Foods is a keenly priced opportunity in an unglamorous sector
By Dr Matthew Partridge Published